Next Article in Journal
Diarylureas: Repositioning from Antitumor to Antimicrobials or Multi-Target Agents against New Pandemics
Next Article in Special Issue
Weighted Gene Co-Expression Network Analysis Identifies Key Modules and Hub Genes Associated with Mycobacterial Infection of Human Macrophages
Previous Article in Journal
Genome-Based Analyses of Fitness Effects and Compensatory Changes Associated with Acquisition of blaCMY-, blaCTX-M-, and blaOXA-48/VIM-1-Containing Plasmids in Escherichia coli
Previous Article in Special Issue
Bioactive Compounds from the Bornean Endemic Plant Goniothalamus longistipetes
Open AccessReview

The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review

by 1,2 and 2,*
1
Department of Biochemistry, University of Cambridge, Hopkins Building, Tennis Court Road, Cambridge CB2 1QW, UK
2
Mycobacteria Research Laboratory, Department of Biological Sciences, The Institute of Structural and Molecular Biology, Birkbeck, University of London, Malet Street, London WC1E 7HX, UK
*
Author to whom correspondence should be addressed.
Received: 18 December 2020 / Revised: 12 January 2021 / Accepted: 16 January 2021 / Published: 19 January 2021
Tuberculosis (TB) remains a global health emergency, with an estimated 2 billion people infected across the world, and 1.4 million people dying to this disease every year. Many aspects of the causative agent, Mycobacterium tuberculosis, make this disease difficult for healthcare and laboratory researchers to fight against, such as unique pathophysiology, latent infection and long and complex treatment regimens, thus causing patient non-compliance with the treatment. Development of new drugs is critical for tackling these problems. Repurposing drugs is a promising strategy for generating an effective drug treatment whilst circumventing many of the challenges of conventional drug development. In this regard, the incorporation of immunomodulatory drugs into the standard regimen to potentiate frontline drugs is found to be highly appealing. Drugs of diverse chemical classes and drug categories are increasingly being evidenced to possess antitubercular activity, both in vitro and in vivo. This article explores and discusses the molecular entities that have shown promise in being repurposed for use in anti-TB adjunctive therapy and aims to provide the most up-to-date picture of their progress. View Full-Text
Keywords: tuberculosis; drug resistance; repurposing; immunomodulatory drugs; NSAIDs; adjunctive therapy; potentiator tuberculosis; drug resistance; repurposing; immunomodulatory drugs; NSAIDs; adjunctive therapy; potentiator
Show Figures

Figure 1

MDPI and ACS Style

Lee, C.; Bhakta, S. The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review. Antibiotics 2021, 10, 91. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10010091

AMA Style

Lee C, Bhakta S. The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review. Antibiotics. 2021; 10(1):91. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10010091

Chicago/Turabian Style

Lee, Chiyun; Bhakta, Sanjib. 2021. "The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review" Antibiotics 10, no. 1: 91. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10010091

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop